156 related articles for article (PubMed ID: 37545226)
1. Machine learning methods revealed the roles of immune-metabolism related genes in immune infiltration, stemness, and prognosis of neuroblastoma.
Mu J; Gong J; Lin P; Zhang M; Wu K
Cancer Biomark; 2023; 38(2):241-259. PubMed ID: 37545226
[TBL] [Abstract][Full Text] [Related]
2. Identification of hub genes and their correlation with infiltration of immune cells in
Chen J; Sun M; Chen C; Jiang B; Fang Y
Front Immunol; 2022; 13():1016683. PubMed ID: 36311753
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a novel stemness-related prognostic model for neuroblastoma using integrated machine learning and bioinformatics analyses.
Xia Y; Wang C; Li X; Gao M; Hogg HDJ; Tunthanathip T; Hulsen T; Tian X; Zhao Q
Transl Pediatr; 2024 Jan; 13(1):91-109. PubMed ID: 38323183
[TBL] [Abstract][Full Text] [Related]
4. [A comprehensive analysis of potential prognostic biomarkers for MYCN-amplified neuroblastoma].
Fan X; Lu HT; Hou L; Zhang L; Yang BY; Chen WM; Zhang HY; Chen X; Li FJ
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Mar; 22(3):262-268. PubMed ID: 32204764
[TBL] [Abstract][Full Text] [Related]
5. A signature based on five immune-related genes to predict the survival and immune characteristics of neuroblastoma.
Ma K; Zhang P; Xia Y; Dong L; Li Y; Liu L; Liu Y; Wang Y
BMC Med Genomics; 2022 Nov; 15(1):242. PubMed ID: 36419120
[TBL] [Abstract][Full Text] [Related]
6. Integration of clinical characteristics and molecular signatures of the tumor microenvironment to predict the prognosis of neuroblastoma.
Cheng H; Zhang L; Yang S; Ren Q; Chang S; Jin Y; Mou W; Qin H; Yang W; Zhang X; Zhang W; Wang H
J Mol Med (Berl); 2023 Nov; 101(11):1421-1436. PubMed ID: 37712965
[TBL] [Abstract][Full Text] [Related]
7. Construction of a novel anoikis-related prognostic model and analysis of its correlation with infiltration of immune cells in neuroblastoma.
Chen J; Sun M; Chen C; Kang M; Qian B; Sun J; Ma X; Zhou J; Huang L; Jiang B; Fang Y
Front Immunol; 2023; 14():1135617. PubMed ID: 37081871
[TBL] [Abstract][Full Text] [Related]
8. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.
Lee E; Lee JW; Lee B; Park K; Shim J; Yoo KH; Koo HH; Sung KW; Park WY
BMC Med Genomics; 2020 Nov; 13(1):171. PubMed ID: 33172452
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of NT5E/CD73 in neuroblastoma and its function in CSC stemness maintenance.
Jain D; Somasundaram DB; Aravindan S; Yu Z; Baker A; Esmaeili A; Aravindan N
Cell Biol Toxicol; 2023 Jun; 39(3):967-989. PubMed ID: 34773529
[TBL] [Abstract][Full Text] [Related]
10. Predicting amplification of
Giwa A; Rossouw SC; Fatai A; Gamieldien J; Christoffels A; Bendou H
Future Oncol; 2021 Dec; 17(34):4769-4783. PubMed ID: 34751044
[TBL] [Abstract][Full Text] [Related]
11. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
12. Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma.
Weng Z; Lin J; He J; Gao L; Lin S; Tsang LL; Zhang H; He X; Wang G; Yang X; Zhou H; Zhao H; Li G; Zou L; Jiang X
Neuro Oncol; 2022 Jun; 24(6):872-885. PubMed ID: 34655293
[TBL] [Abstract][Full Text] [Related]
13. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
14. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
[TBL] [Abstract][Full Text] [Related]
15. A signature of 29 immune-related genes pairs to predict prognosis in patients with neuroblastoma.
Song J; Zhao Q; Xu Y; Zhu L
Int Immunopharmacol; 2020 Nov; 88():106994. PubMed ID: 33182060
[TBL] [Abstract][Full Text] [Related]
16. Gene signatures associated with genomic aberrations predict prognosis in neuroblastoma.
He X; Qin C; Zhao Y; Zou L; Zhao H; Cheng C
Cancer Commun (Lond); 2020 Mar; 40(2-3):105-118. PubMed ID: 32237073
[TBL] [Abstract][Full Text] [Related]
17. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
[TBL] [Abstract][Full Text] [Related]
18. Significance of hematopoietic surface antigen CD34 in neuroblastoma prognosis and the genetic landscape of CD34-expressing neuroblastoma CSCs.
Aravindan N; Somasundaram DB; Herman TS; Aravindan S
Cell Biol Toxicol; 2021 Jun; 37(3):461-478. PubMed ID: 32979173
[TBL] [Abstract][Full Text] [Related]
19. Detection of MYCN Amplification in Serum DNA Using Conventional Polymerase Chain Reaction.
Ma Y; Lee JW; Park SJ; Yi ES; Choi YB; Yoo KH; Sung KW; Koo HH
J Korean Med Sci; 2016 Sep; 31(9):1392-6. PubMed ID: 27510381
[TBL] [Abstract][Full Text] [Related]
20. Identification of
Shao F; Wang Z; Wang S
DNA Cell Biol; 2021 Feb; 40(2):332-347. PubMed ID: 33393844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
